Reply-Reference-Cited by-同舟云学术

Published:2023-06-14 Issue:9 Volume:75 Page:1681-1683
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Xue Xiaomei¹^ORCID,Yan Fei¹^ORCID,Guo Kai¹,He Yuwei²^ORCID,Li Changgui³^ORCID

Affiliation:

1. Department of Endocrinology and Metabolism the Affiliated Hospital of Qingdao University Qingdao China

2. Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout the Affiliated Hospital of Qingdao University Qingdao China

3. Department of Endocrinology and Metabolism Shandong Provincial Key Laboratory of Metabolic Diseases and Qingdao Key Laboratory of Gout Affiliated Hospital of Qingdao University, Institute of Metabolic Diseases, Qingdao University and Shandong Provincial Clinical Research Center for Immune Diseases and Gout Qingdao China

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.42494

Reference10 articles.

1. Superiority of Low‐Dose Benzbromarone to Low‐Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion

2. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort

3. Febuxostat-induced acute liver injury

4. Prospective randomized comparison of effect on coronary endothelial and renal function between febuxostat and benzbromarone in hyperuricemic patients with coronary artery disease: EFEF study

5. Effect of Clinical Typing on Serum Urate Targets of Benzbromarone in Chinese Gout Patients: A Prospective Cohort Study